$9.38
Evolus
Performance
Dividends
-15.62%
1W
1M
YTD
1Y
3Y
20/36
Growth Score
10/36
Dividend Score
Valuation
PE Ratio
-10.62
PS Ratio
2.2
RSI
-
0
PEG Ratio
-0.02
3
PRG Ratio
0.09
PDG Ratio
0
Growth
336%232%231%233%
17%18%43%542%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
98.48%
2
Gross Margin
67.73%
2
Current Ratio
2.34
Return on Assets
-26.34%
Return on Equity
-931.98%
Return on inv. Capital
-24.85%
Institutional Holder
54.055.573057.009.467
1511179
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 266.27M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -50.42M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 182.30M
2018
2019
2020
2021
2022
2023
2024
6
Events
EOLS
Evolus
in 265 days
after market close
Earnings per Share is expected with - and revenue with - .
EOLS
Evolus
in 201 days
after market close
Earnings per Share is expected with - and revenue with - .
EOLS
Evolus
in 83 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Drug Manufacturers - Specialty & Generic
IPO Date
08.02.2018
MaketCap
604.31M
Country
US
CEO
David Moatazedi
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Updated 28.07.2025